Keytruda may make ₩300 billion with 1st-line reimb

By | translator Alice Kang

22.02.28 17:35:08

가나다라 0

Reimbursement expanded to first-line lung cancer and second-line Hodgkin’s lymphoma from March

4,000 additional patients to receive benefits… simple calculation shows a gain of ₩72 million won per patient

First exceeded ₩200 billion in annual sales for the first time last year… is expected to be the first to make ₩300 billion among pharamceuticals

The reimbursement expansion approval of Keytruda is expected to add wings to the sales growth of an already leading product in the domestic pharmaceutical market. It is expected that the company may achieve ₩300 billion in sales with its reimbursement expansion to the first-line, which has more patients, from the ₩200 billion sold last year.

According to industry sources, the insurance benefit for MSD’s PD-1 inhibitor Keytruda (pembrolizumab) will be expanded to first-line treatment of NSCLC. This is the first time an immunotherapy drug was granted reimbursement for the first-line treatment of cancer. Also, a new reimbursement category was prepared for the drug’s use as second or higher-

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)